详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Osimertinib (AZD9291) in Asia-Pacific Patients with T790M Mutation-Positive Advanced NSCLC: Open-Label Phase II Study Results

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

单位： [1]Tongji Univ, Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China [2]Beijing Union Med Coll Hosp, Dept Oncol, Beijing, Peoples R China [3]Canc Hosp Jilin Prov, Dept Oncol, Thorac Oncol, Changchun, Jilin, Peoples R China [4]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Oncol,Canc Ctr, Wuhan, Hubei, Peoples R China [5]Canc Hosp, Dept Pulm & Crit Care Med, Zhengzhou, Henan, Peoples R China [6]Chinese Acad Med Sci, Canc Inst & Hosp, Dept Med Oncol, Beijing, Peoples R China [7]Peking Union Med Coll, Beijing, Peoples R China [8]Tangdu Hosp, Canc Inst, Dept Oncol, Tangdu Comprehens Canc Ctr, Xian, Shaanxi, Peoples R China [9]Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Div Hematol Oncol,Dept Med, Seoul, South Korea [10]Astrazeneca, China Dev Unit, Zhangjiang Hitech Pk, Shanghai, Peoples R China [11]Astrazeneca, Macclesfield, Cheshire, England [12]Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangdzhou, Guangdong, Peoples R China [13]Guangdong Acad Med Sci, Guangdzhou, Guangdong, Peoples R China

出处：

DOI：

ISSN：

关键词： EGFR-TKI T790M osimertinib (AZD9291) EGFR mutation

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2016]版：

大类 | 2 区医学

小类 | 2 区肿瘤学 2 区呼吸系统

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

JCR分区：

出版当年[2015]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

最新[2023]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 21.1 最新[2023版] 16.5 最新五年平均 5.04 出版当年[2015版] 4.932 出版当年五年平均 5.282 出版前一年[2014版] 6.595 出版后一年[2016版]

第一作者：

第一作者单位： [1]Tongji Univ, Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Osimertinib in advanced or metastatic non-small cell lung cancer patients with EGFR T790M mutation after treatment with EGFR-TKI: Interim analysis of China cohort from the single-arm, open-label, international, multi-center real-world ASTRIS study [2]Addition of Local Therapy to EGFR TKI Showed Survival Benefit in EGFR-Mutant NSCLC pts with Oligometastatic or Oligoprogressive Liver Metastases [3]Exploring the impact of EGFR T790M neighboring SNPs on ARMS-based T790M mutation assay [4]Influence of EGFR-TKIs Treatment Lines and PFS on the Emergence of T790M Mutation [5]Dynamic mutation profiles of Chinese patients with EGFR T790M advanced NSCLC receiving osimertinib [6]AZD9291用于EGFR-TKI治疗后T790M阳性晚期非小细胞肺癌的真实世界研究 [7]Detection of EGFR T790M in Asia-Pacific patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Circulating tumour (ct) DNA analysis across 3 platforms [8]Concomitant SBRT and EGFR-TKI Versus EGFR-TKI Alone for Oligometastatic NSCLC: A Multicenter, Randomized Phase II Study [9]EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs [10]Genomic Origin and EGFR-TKI Efficacy of Pulmonary Adenosquamous Carcinoma